Cebiotex is an innovative biotechnology startup, spin-off of the Polytechnic University of Catalonia (Universitat Politècnica de Catalunya – UPC) and the Sant Joan de Déu Barcelona Children’s Hospital (HSJD).
We investigate and develop biomedical solutions with the objective of addressing unmet medical needs in both paediatric and adult oncology.
The Cebiotex project started when 6-year-old Sara passed away after 4 years fighting child cancer. This experience motivated the founder Joan Bertran to investigate and develop new biomaterials that could bring medical solutions to paediatric and adult oncology, expanding to the health sector.
After three years of combined scientific work, Cebiotex was constituted in 2012 as a result of the interaction between researchers from the UPC and the HSJD. Our spin-off started its activity after closing the first funding round in 2015.
Our current mission is to provide solutions to patients with cancer, both paediatric and adult. Our future perspective is to also provide solutions to patients who suffer from infections or who need advanced therapies for marrow and cartilage regeneration, marrow injuries, etc.
Our first drug, CEB-01, meets an oncological and surgical need that has not yet been met by helping surgeons in their surgical oncology interventions.
Our objective is for CEB-01 to become part of the Standard of Care in surgical oncology.
We are working on the development of the drug CEB-01 with the objective of meeting unmet medical needs in oncology, and ensure surgeons and patients that the surgical site is free from cancerous cells.
After finalising the Preclinical Phase with extremely promising results, we have initiated the Clinical Phase 2a. We are currently studying the security of CEB-01 in the indication of Soft Tissue Sarcomas (STS) with adult patients at Hospital de la Santa Creu i Sant Pau in Barcelona.
Cebiotex is formed by a multidisciplinary team of expert professionals which includes founders, pharmaceutical regulatory advisors, business developers, finance and communications experts, and a scientific committee that advises on the project’s Clinical Phase.
ASCO21: First-in-human administration of CEB-01, a novel drug delivery implant matrix, in patients with recurrent or locally advanced retroperitoneal soft tissue sarcoma (RPS) after surgery: Preliminary safety and pharmacokinetics report. …
Click here to read the online article.
In only six weeks, Cebiotex’s crowdfunding round on Capital Cell has successfully closed, achieving the set objective of 600,000€ and reaching 125% of investment, with 750,000€ The total amount of …
On December 15, Cebiotex received the Seal of Excellence awarded by the European Commission. The Seal of Excellence is a quality label awarded to project proposals submitted to Horizon 2020, …
Cover of the BioRegió de Catalunya report. Source: Biocat and CataloniaBio & HealthTech. Cebiotex has been highlighted in the recent ‘BioRegió de Catalunya 2020’ report among the nine Biotech and …
Haz clic aquí para leer el artículo:
Dr. Lucas Krauel and Dr. JA González at the Hospital de la Santa Creu i Sant Pau de Barcelona. Promising results after the implant of CEB-01, currently in Clinical Phase …
Founder and CEO Joan Bertran accepting the award. Cebiotex has been renowned with the Cecot Recognition of Innovation prize 2018. Joan Bertran, CEO and founder of Cebiotex, received the award …
